Recap: VistaGen Therapeutics Q1 Earnings
Shares of VistaGen Therapeutics (NASDAQ:VTGN) fell 1.5% in after-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share were up 42.86% over the past year to ($0.04), which beat the estimate of ($0.05).
VistaGen Therapeutics Q1 EPS $(0.04) Up From $(0.07) YoY, Sales $354.10K
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.04) per share. This is a 42.86 percent increase over losses of $(0.07) per share from the same period last year. The company reported $354.10 thousand
VistaGen Therapeutics Insights: Return On Capital Employed
During Q4, VistaGen Therapeutics's (NASDAQ:VTGN) reported sales totaled $441.90 thousand. Despite a 17.36% in earnings, the company posted a loss of $6.22 million. In Q3, VistaGen Therapeutics brought in $313.60 thousand in sales but lost $5.30 million in earnings.
Stocks That Hit 52-Week Highs On Friday
Before 10 a.m. ET Friday, 146 stocks hit new 52-week highs.
The Daily Biotech Pulse: Iterum’s Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 1)
72 Biggest Movers From Yesterday
Gainers
Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share.
VistaGen Therapeutics: Q4 Earnings Insights
Shares of VistaGen Therapeutics (NASDAQ:VTGN) decreased in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share decreased 328.57% over the past year to ($0.30), which missed the estimate of ($0.05).